The Food and Drug Administration Friday approved the first generic naloxone nasal spray, an emergency treatment for opioid overdose intended for use in the community. Generic injectable naloxone products have been available for use in health care settings for years. The FDA has previously approved a brand-name naloxone nasal spray and an auto-injector for use by those without medical training. “In addition to this approval of the first generic naloxone nasal spray, moving forward we will prioritize our review of generic drug applications for naloxone,” said Douglas Throckmorton, M.D., deputy center director for regulatory programs at the FDA’s Center for Drug Evaluation and Research.

Related News Articles

Headline
Under a new Centers for Medicare…
Headline
Six health care organizations in rural North Carolina communities will share $1.2 million in federal grant funds to strengthen and expand their response to…
Headline
The Food and Drug Administration yesterday released new draft guidance for labeling medications that carry the risk of abuse or dependence, including but not…
Headline
The National Academy of Medicine Action Collaborative on Countering the U.S. Opioid Epidemic will host a free public webinar July 22 at 3 p.m. ET on best…
Headline
The Department of Health and Human Services has agreed to delay implementing its final rule concerning certain statutory conscience rights in health care, San…
Headline
The Centers for Medicare…